Published in Medical Letter on the CDC and FDA, October 25th, 2009
The company has attracted a great deal of interest from the biomedical investment community and while some Wall Street reporters have painted the company as little more than the latest "flu stock" play, the fact remains that both the FDA and the medical research community has taken notice...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Medical Letter on the CDC and FDA
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.